These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 19051373)

  • 21. When There's No Cure: My Brother's Battle With Drug-Resistant TB.
    Aleksanyan S
    Health Aff (Millwood); 2016 Feb; 35(2):371-4. PubMed ID: 26858393
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Totally drug resistant tuberculosis?].
    Dahle UR
    Tidsskr Nor Laegeforen; 2012 Mar; 132(6):634. PubMed ID: 22456141
    [No Abstract]   [Full Text] [Related]  

  • 23. Extensively drug-resistant Mycobacterium tuberculosis: what are these bugs up to in India?
    Dheda K
    Indian J Med Res; 2009 Oct; 130(4):357-8. PubMed ID: 19942736
    [No Abstract]   [Full Text] [Related]  

  • 24. Treatment of extensively drug-resistant tuberculosis.
    Silva JM; Fuchs SC; Barcellos NT; Zavascki AP
    Lancet; 2009 Jan; 373(9657):27; author reply 27-8. PubMed ID: 19121717
    [No Abstract]   [Full Text] [Related]  

  • 25. Development of a standardised multidrug-resistant/extensively drug-resistant tuberculosis assessment and monitoring tool.
    Migliori GB; Sotgiu G; Jaramillo E; Mirzayev F; Centis R; Colvin C; Richardson MD
    Int J Tuberc Lung Dis; 2009 Oct; 13(10):1305-8. PubMed ID: 19793438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of extensively drug-resistant tuberculosis in Vladimir and Orel regions, Russia.
    Punga VV; Jakubowiak WM; Danilova ID; Somova TR; Volchenkov GV; Kazionnyy BY; Nemtsova ES; Kiryanova EV; Kourbatova EV
    Int J Tuberc Lung Dis; 2009 Oct; 13(10):1309-12. PubMed ID: 19793439
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis.
    Tiberi S; Sotgiu G; D'Ambrosio L; Centis R; Arbex MA; Alarcon Arrascue E; Alffenaar JW; Caminero JA; Gaga M; Gualano G; Skrahina A; Solovic I; Sulis G; Tadolini M; Alarcon Guizado V; De Lorenzo S; Roby Arias AJ; Scardigli A; Akkerman OW; Aleksa A; Artsukevich J; Avchinko V; Bonini EH; Chong Marín FA; Collahuazo López L; de Vries G; Dore S; Kunst H; Matteelli A; Moschos C; Palmieri F; Papavasileiou A; Payen MC; Piana A; Spanevello A; Vargas Vasquez D; Viggiani P; White V; Zumla A; Migliori GB
    Clin Infect Dis; 2016 May; 62(9):1188-90. PubMed ID: 26908794
    [No Abstract]   [Full Text] [Related]  

  • 28. Extensively drug-resistant tuberculosis.
    Dheda K; Shean K; Badri M
    N Engl J Med; 2008 Nov; 359(22):2390; author reply 2391. PubMed ID: 19038886
    [No Abstract]   [Full Text] [Related]  

  • 29. Access sought to tuberculosis drug from nutraceutical company.
    Gruber K
    Nat Med; 2015 Feb; 21(2):103. PubMed ID: 25642939
    [No Abstract]   [Full Text] [Related]  

  • 30. Treatment of drug-resistant tuberculosis.
    Ajbani K; Soman R; Shetty A; Rodrigues C
    Lancet Infect Dis; 2011 Sep; 11(9):660; author reply 660-1. PubMed ID: 21867954
    [No Abstract]   [Full Text] [Related]  

  • 31. Treatment of drug-resistant tuberculosis.
    Mishra GP
    Lancet Infect Dis; 2011 Sep; 11(9):659-60; author reply 660-1. PubMed ID: 21867952
    [No Abstract]   [Full Text] [Related]  

  • 32. Target regimen profiles for treatment of tuberculosis: a WHO document.
    Lienhardt C; Nahid P; Rich ML; Bansbach C; Kendall EA; Churchyard G; González-Angulo L; D'Ambrosio L; Migliori GB; Raviglione M
    Eur Respir J; 2017 Jan; 49(1):. PubMed ID: 28122858
    [No Abstract]   [Full Text] [Related]  

  • 33. Compassionate and optimum use of new tuberculosis drugs.
    Reed C; Mason L; Cox H; Seaworth B; Lessem E; Furin J
    Lancet Infect Dis; 2015 Oct; 15(10):1131. PubMed ID: 26461942
    [No Abstract]   [Full Text] [Related]  

  • 34. Good news about a bad subject: scientific evidence to help defeat multidrug/extensively drug-resistant tuberculosis.
    Sotgiu G; Woodhead M
    Eur Respir J; 2014 Jul; 44(1):5-7. PubMed ID: 24982046
    [No Abstract]   [Full Text] [Related]  

  • 35. Extensively drug-resistant tuberculosis: early access to bedaquiline for a UK patient.
    van Halsema C; Humphreys S; Bonington A
    Eur Respir J; 2014 Jan; 43(1):292-4. PubMed ID: 23988770
    [No Abstract]   [Full Text] [Related]  

  • 36. Linezolid for extensively drug-resistant tuberculosis.
    Dhooria S; Agarwal R; Behera D
    N Engl J Med; 2013 Jan; 368(3):290-1. PubMed ID: 23323918
    [No Abstract]   [Full Text] [Related]  

  • 37. Linezolid for extensively drug-resistant tuberculosis.
    Cattaneo D; Orlando G; Cordier L
    N Engl J Med; 2013 Jan; 368(3):291. PubMed ID: 23323919
    [No Abstract]   [Full Text] [Related]  

  • 38. Linezolid for extensively drug-resistant tuberculosis.
    Jaramillo E; Weyer K; Raviglione M
    N Engl J Med; 2013 Jan; 368(3):290. PubMed ID: 23323917
    [No Abstract]   [Full Text] [Related]  

  • 39. [The course of a process and the efficiency of treatment of pulmonary tuberculosis patients excreting Mycobacterium tuberculosis with extensive drug resistance to antituberculous drugs].
    Mishin VIu; Komissarova OG; Chukanov VI; Kononets AS
    Probl Tuberk Bolezn Legk; 2009; (2):50-2. PubMed ID: 19382643
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Do we have evidence for policy changes in the treatment of children with latent tuberculosis infection?
    Lobato MN; Jereb JA; Castro KG
    Pediatrics; 2009 Mar; 123(3):902-3. PubMed ID: 19255018
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.